{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triple+IT+Therapy",
    "query": {
      "intervention": "Triple IT Therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 51,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triple+IT+Therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T08:31:18.636Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05253495",
      "title": "Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-hodgkin Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "DOC Group B",
          "type": "DRUG"
        },
        {
          "name": "Pv-COMRAD 1 and 2 Group B",
          "type": "DRUG"
        },
        {
          "name": "Pv-R-CYM 1 and 2 Group B",
          "type": "DRUG"
        },
        {
          "name": "DOC Group C",
          "type": "DRUG"
        },
        {
          "name": "MAD CPR 1 and 2",
          "type": "DRUG"
        },
        {
          "name": "Pv-R CYVE 1 and 2",
          "type": "DRUG"
        },
        {
          "name": "Pv-R CYVE-MTX 1 and 2",
          "type": "DRUG"
        },
        {
          "name": "MAD CP",
          "type": "DRUG"
        },
        {
          "name": "Pv-Cytarabine/etoposide",
          "type": "DRUG"
        },
        {
          "name": "AD CP",
          "type": "DRUG"
        },
        {
          "name": "Bv-AVD-R 1 and 2: COHORT IIa",
          "type": "DRUG"
        },
        {
          "name": "Bv-NVD-R, Cycle 1-2",
          "type": "DRUG"
        },
        {
          "name": "Bv-NVD-R, Cycle 1-4 SER",
          "type": "DRUG"
        },
        {
          "name": "Bv-AVD-R",
          "type": "DRUG"
        },
        {
          "name": "Bv-NVD-R, Cycle 1-4 RER",
          "type": "DRUG"
        },
        {
          "name": "Bv-NAVD-R, Cycle 1-2",
          "type": "DRUG"
        },
        {
          "name": "Involved Site Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Years to 39 Years"
      },
      "enrollment_count": 80,
      "start_date": "2022-02-01",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Gainsville, Florida • Vallhala, New York",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        },
        {
          "city": "Vallhala",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05253495"
    },
    {
      "nct_id": "NCT07645326",
      "title": "RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)"
      ],
      "interventions": [
        {
          "name": "Androgen Deprivation Therapy (ADT)",
          "type": "DRUG"
        },
        {
          "name": "Androgen Receptor Pathway Inhibitor (ARPI)",
          "type": "DRUG"
        },
        {
          "name": "Prostate Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 108,
      "start_date": "2026-08",
      "completion_date": "2032-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07645326"
    },
    {
      "nct_id": "NCT06483555",
      "title": "Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Metastatic Pancreatic Cancer",
        "Basal Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "NALIRIFOX",
          "type": "DRUG"
        },
        {
          "name": "Folfirinox",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2025-02-06",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06483555"
    },
    {
      "nct_id": "NCT04787042",
      "title": "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Triple-negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Carcinoma",
        "MSI-High"
      ],
      "interventions": [
        {
          "name": "ST-067",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Simcha IL-18, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 316,
      "start_date": "2021-08-06",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04787042"
    },
    {
      "nct_id": "NCT03194932",
      "title": "Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Intrathecal Triple Therapy",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "2 Years to 20 Years"
      },
      "enrollment_count": 62,
      "start_date": "2017-07-11",
      "completion_date": "2022-06-22",
      "has_results": false,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03194932"
    },
    {
      "nct_id": "NCT03618823",
      "title": "Non-opioids for Analgesia After Adenotonsillectomy in Children",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenotonsillectomy",
        "Post-operative Analgesia",
        "Opioid Use"
      ],
      "interventions": [
        {
          "name": "Oxycodone",
          "type": "DRUG"
        },
        {
          "name": "Ibuprofen",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Chi, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 268,
      "start_date": "2018-10-25",
      "completion_date": "2020-05-18",
      "has_results": true,
      "last_update_posted_date": "2021-11-10",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03618823"
    },
    {
      "nct_id": "NCT02270788",
      "title": "Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Crenolanib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "methotrexate, hydrocortisone and cytarabine with leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "1 Year to 39 Years"
      },
      "enrollment_count": 10,
      "start_date": "2015-04-02",
      "completion_date": "2016-10-17",
      "has_results": false,
      "last_update_posted_date": "2017-10-03",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02270788"
    },
    {
      "nct_id": "NCT00002970",
      "title": "506U78 in Treating Patients With Refractory Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "T-cell Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "nelarabine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "therapeutic hydrocortisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 148,
      "start_date": "1997-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-07-02",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002970"
    },
    {
      "nct_id": "NCT03815331",
      "title": "Xiaflex® Plus Testosterone Treatment Pilot Study Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peyronie's Disease (PD)"
      ],
      "interventions": [
        {
          "name": "Xiaflex®",
          "type": "DRUG"
        },
        {
          "name": "Aveed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Men's Health Boston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "18 Years to 70 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2019-01-14",
      "completion_date": "2020-12-30",
      "has_results": false,
      "last_update_posted_date": "2020-12-31",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 1,
      "location_summary": "Chestnut Hill, Massachusetts",
      "locations": [
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03815331"
    },
    {
      "nct_id": "NCT03013998",
      "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Samalizumab (BAML-16-001-S1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BI 836858 (BAML-16-001-S2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Daunorubicin (BAML-16-001-S1)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S1)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S2)",
          "type": "DRUG"
        },
        {
          "name": "AG-221 (BAML-16-001-S3)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S3)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S4)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S4)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S5)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S5)",
          "type": "DRUG"
        },
        {
          "name": "Entospletinib (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S6)",
          "type": "DRUG"
        },
        {
          "name": "Pevonedistat (BAML-16-001-S9)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S9)",
          "type": "DRUG"
        },
        {
          "name": "AG-120 (BAML-16-001-S16)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S16)",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib (BAML-16-001-S8 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S8 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "AZD5153 (BAML-16-001-S10)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S10)",
          "type": "DRUG"
        },
        {
          "name": "TP-0903 (BAML-16-001-S14)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S14)",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "AZD5991 (BAML-16-001-S18)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S18)",
          "type": "DRUG"
        },
        {
          "name": "SNDX-5613 (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S17)",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib (BAML-16-001-S8 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S12 Arm A)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S12 Arm A)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S12 Arm B)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S12 Arm B)",
          "type": "DRUG"
        },
        {
          "name": "ZE46-0134 (BAML-16-001-S21 Group 1)",
          "type": "DRUG"
        },
        {
          "name": "ficlatuzumab (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax (BAML-16-001-S24)",
          "type": "DRUG"
        },
        {
          "name": "ZE46-0134 (BAML-16-001-S21 Group 2)",
          "type": "DRUG"
        },
        {
          "name": "Bleximenib (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (BAML-16-001-S25/HO181)",
          "type": "DRUG"
        },
        {
          "name": "Revumenib (BAML-16-001-S26/HO177)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (BAML-16-001-S26/HO177)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Beat AML, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2016-11",
      "completion_date": "2032-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-08T08:31:18.636Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03013998"
    }
  ]
}